Latvijā cirkulējošo HIV-1 ģenētisko variantu izplatība un filoģenētiskā analīze.
Date
2009
Authors
Vrubļevska-Ludiņa, Jolanta
Journal Title
Journal ISSN
Volume Title
Publisher
Latvijas Universitāte
Abstract
Latvijā cirkulējošo HIV-1 genētisko variantu izplatība un filogenētiskā analīze.
Pamatojums: HIV-1 rezistence ir viens no galvenajiem faktoriem, kas limitē HIV/AIDS terapijas efektivitāti indivīda un populācijas līmenī.
Mērķis: Noskaidrot Latvijā cirkulējošo HIV -1 ģenētisko variantu izplatību un dinamiku dažādās iedzīvotāju riska grupās un veikt to filoģenētisko analīzi.
Metodes: HIV genotipēšana ar Trugene HIV-1 genotipēšanas komplektu (BayerHealthCare-diagnostics) 127 pacientiem pirms HAART uzsākšanas un 115 pacientiem, sakarā ar terapijas neefektivitāti. HIV-1 subtipi noteikti ar Rega 2.0, filoģēnetiskajai analīzei-Mega 4.0. Ar HIV-1 rezistenci asociēto mutāciju un to kombināciju izplatība Latvijā analizēta saskaņā ar IAS - USA mutāciju paneli (2008.g.), un W. Shafer mutāciju sarakstu primāras rezistences pētīšanai (2007.g.).
Rezultāti: Neārstēto pacientu grupā primārās zāļu rezistences prevalence-6,3%, atklāta rezistence pret NRTI-lamivudīnu (3TC), pret NNRTI-nevirapīnu (NVP) un efavirencu (EFV), pret PI-sakinaviru (SQV), indinaviru (IND), nelfinaviru (NFV). Ārstēto pacientu grupā zāļu rezistence 50%: pret NRTI-43%, pret NNRTI-22% un PI-15%. Populācijā dominē HIV-1 A subtips-79% un B subtips-19%.
Secinājums: Genotipēšanas rezultāti ir pielietojami HIV-1 molekulārās epidemioloģijas raksturošanai.
Atslēgas vārdi: HIV, zāļu rezistence, HIV subtips, HAART, NRTI, NNRTI, PI
Prevalence and Phylogenetic Analysis of HIV-1 Genetic Variants Circulating in Latvia. Background: HIV-1 drug resistance is one of the main factors limiting the efficiency of HIV/AIDS therapy at individual level and that of whole population. Aim: to establish the prevalence and dynamics of HIV-1 genetic variants within various risk groups as well as to perform their phylogenetic analysis Methods: HIV genotyping applying Trugene HIV-1 genotyping kit (BayerHealthCare-diagnostics) on 127 treatment naive individuals before HAART therapy and 115 treatment-experienced individuals with treatment failures. HIV-1 subtyping was established applying Rega 2.0, phylogenetic analysis was performed with Mega 4.0. The prevalence of HIV drug resistance associated mutations (RAMs) in Latvia were detected according to IAS -USA mutation list (2008), and R.W. Shafer mutation list (2007). Results: Transmitted drug resistance in treatment naive group was 6.3%, there was detected resistance to NRTI-lamivudine (3TC), NNRTI-nevirapine (NVP) un efavirence(EFV), to PI-saquinavir (SQV), indinavir (IND), nelfinavir (NFV). HIV drug resistance in treatment experienced was 50%: to NRTI-43%, to NNRTI-22% and to PI-15%. Most frequently observed HIV-1 subtypes was subtype A-79% and subtype B -19%. Conclusion: Genotyping can be used for describing molecular-epidemiology of HIV-1. Key words: HIV, drug resistance, HIV subtype, HAART, NRTI, NNRTI, PI
Prevalence and Phylogenetic Analysis of HIV-1 Genetic Variants Circulating in Latvia. Background: HIV-1 drug resistance is one of the main factors limiting the efficiency of HIV/AIDS therapy at individual level and that of whole population. Aim: to establish the prevalence and dynamics of HIV-1 genetic variants within various risk groups as well as to perform their phylogenetic analysis Methods: HIV genotyping applying Trugene HIV-1 genotyping kit (BayerHealthCare-diagnostics) on 127 treatment naive individuals before HAART therapy and 115 treatment-experienced individuals with treatment failures. HIV-1 subtyping was established applying Rega 2.0, phylogenetic analysis was performed with Mega 4.0. The prevalence of HIV drug resistance associated mutations (RAMs) in Latvia were detected according to IAS -USA mutation list (2008), and R.W. Shafer mutation list (2007). Results: Transmitted drug resistance in treatment naive group was 6.3%, there was detected resistance to NRTI-lamivudine (3TC), NNRTI-nevirapine (NVP) un efavirence(EFV), to PI-saquinavir (SQV), indinavir (IND), nelfinavir (NFV). HIV drug resistance in treatment experienced was 50%: to NRTI-43%, to NNRTI-22% and to PI-15%. Most frequently observed HIV-1 subtypes was subtype A-79% and subtype B -19%. Conclusion: Genotyping can be used for describing molecular-epidemiology of HIV-1. Key words: HIV, drug resistance, HIV subtype, HAART, NRTI, NNRTI, PI
Description
Keywords
Bioloģija